| FAQ/Help |
| Calendar |
| Search |
| Today's Posts |
05-05-2017, 08:06 AM
|
#1 | ||
|
|||
|
Member
|
Living Cell Technologies Limited has completed treatment of all six patients in the third and final group of patients in the Phase IIb clinical trial of NTCELL for Parkinson’s disease, at Auckland City Hospital (New Zealand).
http://www.lctglobal.com/upload/news...0completed.pdf (hat tip to catlou at HU for the heads-up) |
||
|
 Reply With Quote
|
| "Thanks for this!" says: | lab rat (05-05-2017) |
| Reply |
|
|
Similar Threads
|
||||
| Thread | Forum | |||
| Approval granted to LCT for group 3 of the phase llb trial of NTCELL | Parkinson's Disease | |||
| Group 2 Parkinson’s trial patients ’ treatment completed | Parkinson's Disease | |||
| CLINICAL TRIAL...Phase III Trial with Pimavanserin in Patients with PD Psychosis | Parkinson's Disease Clinical Trials | |||
Treatment completed for all patients in LCT's NTCELL Phase IIb trial (New Zealand)
Linear Mode
